解放军医药杂志2016，Vol.28Issue(9)：51-54,4.DOI:10.3969/j.issn.2095-140X.2016.09.014
索拉非尼治疗不同年龄转移性肾癌的长期效果观察
Long-term Efficacy of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Different Ages of Patients
摘要
Abstract
Objective To investigate long-term safety and efficacy of Sorafenib in treatment of different ages of patients with metastatic renal cell carcinoma. Methods Clinical data of 30 patients with metastatic renal cell carcinoma treated by Sorafenib was retrospectively analyzed, and the patients were divided into group A (≥60 years old, n=12) and group B ( <60 years old, n=18 ) . Category and degree of adverse reactions, turnover and clinical efficacy were compared in two groups. Results There were no significant differences in category and degree in two groups ( P >0. 05). In group A, disease control rate (DCR) was 83. 3%, and progression-free survival (PFS) time was 12 months, and overall survival (OS) time was 16 months. In group B, DCR was 77. 7%, and PFS time was 15 months, and OS time was 19 months. There were no statistical differences in above indexes in two groups (P>0. 05). Conclusion Sor-afenib in treatment of elder patients with metastatic renal cell carcinoma has good long-term safety and efficacy, and it can be used for patients in different ages.关键词
肾肿瘤/索拉非尼/治疗结果/药物毒性Key words
Kidney neoplasms/Sorafenib/Treatment outcome/Drug toxicity分类
医药卫生引用本文复制引用
杨琳,于世英,熊慧华,邱红..索拉非尼治疗不同年龄转移性肾癌的长期效果观察[J].解放军医药杂志,2016,28(9):51-54,4.基金项目
国家自然科学基金(81372664、81372434) （81372664、81372434）
湖北省自然科学基金(2015CFB541) （2015CFB541）
